Vimseltinib Explained

Cas Number:	1628606-05-2
Pubchem:	86267612
Iuphar Ligand:	11190
Drugbank:	DB17520
Chemspiderid:	95499700
Unii:	PX9FTM69BF
Kegg:	D12238
Chembl:	5095202
Iupac Name:	3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
C:	23
H:	25
N:	7
O:	2
Smiles:	CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
Stdinchi:	1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
Stdinchikey:	TVGAHWWPABTBCX-UHFFFAOYSA-N

Vimseltinib is an investigational new drug that is being evaluated to treat tenosynovial giant cell tumor.^[1] It is a macrophage colony-stimulating factor receptor antagonist.^[2]

Notes and References

Web site: Vimseltinib - Deciphera Pharmaceuticals . AdisInsight . Springer Nature Switzerland AG .
Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, Vogeti L, Vogeti S, Kaufman MD, Wise SC, Le Bourdonnec B, Smith BD, Flynn DL . Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT) . Bioorganic & Medicinal Chemistry Letters . 74 . 128928 . October 2022 . 35961460 . 10.1016/j.bmcl.2022.128928 . free .